Chemed spent $96 million reacquiring Roto-Rooter franchise territories during 2026.
VITAS Healthcare increased average daily patient census by 9.4%.
Paid search leads accounted for 60% of total Roto-Rooter leads.
On its third-quarter 2026 earnings call, held on Oct. 28, 2026, Chemed (NYSE:CHE) announced that it expects full-year adjusted earnings per share (EPS), a measure of net income excluding one-off costs, to finish at or slightly above the top end of its previous guidance. The company combines end-of-life care with nationwide residential plumbing services, generating steady operational cash flow to fund share repurchases and strategic franchise buybacks.
Three things management said stand out.
Chemed spent $96 million in 2026 to reacquire Roto-Rooter franchise territories across California and Texas. While these acquired territories initially operate at lower earnings before interest, taxes, depreciation, and amortization (EBITDA) margins, management expects top-line revenue to expand rapidly as operations integrate.
Top line growth is immediate. And then the EBITDA margin comes. ... So I think it is definitely a good long term acquisition for the company just in the in the near term, it will mute overall margins a little bit.
-- Michael D. Witzeman, Chief Financial Officer
VITAS Healthcare, Chemed's hospice subsidiary, drove revenue growth through higher patient days of care and back-office cost discipline. Targeted recruitment and electronic staffing tools allowed management to meet rising patient demand without experiencing severe hiring friction.
So the short answer is, no issues in hiring. And no significant wage pressures that we are concerned about at this time.
-- Joel L. Wherley, President and Chief Executive Officer of VITAS Healthcare
Roto-Rooter faces persistent marketing headwinds as internet search platforms charge higher fees per lead while reducing non-paid organic placement. Management relies on brand equity, direct commercial accounts, and higher average prices per job to offset marketing expense pressures.
Over 50% of our Roto Rooter customers are repeat customers. In other words, they come to the Internet looking for Roto Rooter. ... And it really comes down to the strength of the Roto Rooter service mark.
-- Kevin J. McNamara, President and Chief Executive Officer
Patient census growth is accelerating across healthcare settings, and Chemed benefits from brand recognition alongside centralized administrative scale. Management is watching lead acquisition costs at Roto-Rooter and admission mix at VITAS Healthcare to maintain long-term profitability.
We believe VITAS is exceptionally well positioned to capitalize on future growth opportunities We look forward to executing our strategy for the remainder of 2026 and beyond that will translate into high sustainable growth while providing the best possible care to our patients.
-- Joel L. Wherley, President and Chief Executive Officer of VITAS Healthcare
Strategic reacquisitions of independent plumbing territories will expand owned branch coverage over the next 12 to 18 months. As operations normalize, management expects operating leverage to assert itself across the branch network.
Roto Rooter has demonstrated a long history of growing margins through cost containment, so long as revenue growth is stable. We fully anticipate Roto Rooter to return to that historic pattern through 2027 and beyond.
-- Kevin J. McNamara, President and Chief Executive Officer
Before you buy stock in Chemed, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Chemed wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $327,620!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $959,410!*
Now, it’s worth noting Stock Advisor’s total average return is 802% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 17, 2026.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.